Comparability of EORTC and DAPROCA studies in advanced prostatic cancer

S Suciu, R Sylvester, P Iversen, I Christensen, L Denis

    2 Citations (Scopus)


    Very often not enough patients are entered and/or the follow-up is insufficient to be able to draw valid conclusions in cancer clinical trials. In this article, we discuss the possibility of pooling the data from two or more trials asking the same or similar questions in order to overcome such problems. How comparable the studies should be for combining their data, in terms of design, patient population, follow-up, and end-points, is discussed in the first part of this paper. Whether these general considerations were completely or partially fulfilled in the two prostatic studies of the EORTC and DAPROCA is the subject of the second part of this article. Problems of interpreting apparently contradictory results, like the superiority of zoladex and flutamide over orchidectomy in terms of time to progression with no clear superiority in terms of overall duration of survival, is also discussed.
    Original languageEnglish
    Issue number5 Suppl
    Pages (from-to)1029-34
    Number of pages6
    Publication statusPublished - 1990


    • Aged
    • Antineoplastic Combined Chemotherapy Protocols
    • Buserelin
    • Flutamide
    • Goserelin
    • Humans
    • Male
    • Orchiectomy
    • Prostatic Neoplasms
    • Randomized Controlled Trials as Topic
    • Survival Rate


    Dive into the research topics of 'Comparability of EORTC and DAPROCA studies in advanced prostatic cancer'. Together they form a unique fingerprint.

    Cite this